Remarkably, the BRD4-destabilizing drug (dBET1), as well as the Stat3 degrader based on a thalidomide-linked molecule of a Stat3 inhibitor, are significantly more effective than parental inhibitors, in murine models of leukemia and lymphoma [123,124], thus highlighting the high therapeutic potential of PROTACs. Here, STAT3 is linked to lymphoma.